Prevalence and Prognostic Significance of Sarcopenia in Gynecologic Oncology: A Systematic Review and Meta-Analysis

IF 9.4 1区医学 Q1 GERIATRICS & GERONTOLOGY

Journal of Cachexia Sarcopenia and Muscle Pub Date : 2025-02-02 DOI:10.1002/jcsm.13699

Chen Jiang, Qin Chen, Danping Yu, Qianqian Zhou, Cong Tang, Chenping Qiao

{"title":"Prevalence and Prognostic Significance of Sarcopenia in Gynecologic Oncology: A Systematic Review and Meta-Analysis","authors":"Chen Jiang, Qin Chen, Danping Yu, Qianqian Zhou, Cong Tang, Chenping Qiao","doi":"10.1002/jcsm.13699","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Sarcopenia in gynaecologic oncology patients has garnered increasing attention, but its prevalence has not been comprehensively summarized. This study aims to integrate the prevalence of sarcopenia in this population through systematic evaluation and meta-analysis, providing a reference for future clinical research.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A computerized search of PubMed, Embase, The Cochrane Library, Web of Science and other databases was conducted to collect relevant literature on the prevalence of sarcopenia in gynaecologic oncology patients and its impact on prognosis, with a timeframe from the inception of the databases to July 2024. Two researchers independently screened the literature, extracted information and assessed the risk of bias. After evaluating the risk of bias, a meta-analysis was performed using RevMan5.4 software. This systematic review was conducted using a previously published study protocol (PROSPERO: CRD42024565094).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 24 studies encompassing 4136 patients were included. The meta-analysis revealed that the prevalence of sarcopenia in gynaecologic oncology patients was 38.8% (<i>I</i><sup>2</sup> = 96%, 95% CI [0.49–0.79], <i>p</i> < 0.001). Subgroup analysis indicated that the prevalence of sarcopenia was higher among patients with endometrial cancer or ovarian cancer, those over 60 years of age, individuals with a body mass index (BMI) greater than 25 kg/m<sup>2</sup>, those diagnosed using the psoas muscle index (PMI) and patients assessed at the L4 vertebra. Overall survival (OS) was significantly lower in patients with gynaecologic tumours combined with sarcopenia compared to those with gynaecologic tumours alone. However, no significant differences were observed in progression-free survival (PFS), mortality or length of hospital stay.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Sarcopenia has a high prevalence in gynaecologic oncology patients. Healthcare professionals should prioritize early screening and preventive measures for high-risk patients.</p>\n </section>\n </div>","PeriodicalId":48911,"journal":{"name":"Journal of Cachexia Sarcopenia and Muscle","volume":"16 1","pages":""},"PeriodicalIF":9.4000,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13699","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cachexia Sarcopenia and Muscle","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcsm.13699","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Sarcopenia in gynaecologic oncology patients has garnered increasing attention, but its prevalence has not been comprehensively summarized. This study aims to integrate the prevalence of sarcopenia in this population through systematic evaluation and meta-analysis, providing a reference for future clinical research.

Methods

A computerized search of PubMed, Embase, The Cochrane Library, Web of Science and other databases was conducted to collect relevant literature on the prevalence of sarcopenia in gynaecologic oncology patients and its impact on prognosis, with a timeframe from the inception of the databases to July 2024. Two researchers independently screened the literature, extracted information and assessed the risk of bias. After evaluating the risk of bias, a meta-analysis was performed using RevMan5.4 software. This systematic review was conducted using a previously published study protocol (PROSPERO: CRD42024565094).

Results

A total of 24 studies encompassing 4136 patients were included. The meta-analysis revealed that the prevalence of sarcopenia in gynaecologic oncology patients was 38.8% (I² = 96%, 95% CI [0.49–0.79], p < 0.001). Subgroup analysis indicated that the prevalence of sarcopenia was higher among patients with endometrial cancer or ovarian cancer, those over 60 years of age, individuals with a body mass index (BMI) greater than 25 kg/m², those diagnosed using the psoas muscle index (PMI) and patients assessed at the L4 vertebra. Overall survival (OS) was significantly lower in patients with gynaecologic tumours combined with sarcopenia compared to those with gynaecologic tumours alone. However, no significant differences were observed in progression-free survival (PFS), mortality or length of hospital stay.

Conclusion

Sarcopenia has a high prevalence in gynaecologic oncology patients. Healthcare professionals should prioritize early screening and preventive measures for high-risk patients.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cachexia Sarcopenia and Muscle MEDICINE, GENERAL & INTERNAL-

CiteScore

13.30

自引率

12.40%

发文量

234

审稿时长

16 weeks

期刊介绍： The Journal of Cachexia, Sarcopenia and Muscle is a peer-reviewed international journal dedicated to publishing materials related to cachexia and sarcopenia, as well as body composition and its physiological and pathophysiological changes across the lifespan and in response to various illnesses from all fields of life sciences. The journal aims to provide a reliable resource for professionals interested in related research or involved in the clinical care of affected patients, such as those suffering from AIDS, cancer, chronic heart failure, chronic lung disease, liver cirrhosis, chronic kidney failure, rheumatoid arthritis, or sepsis.